Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease

Alex George; Bogdan Dinu; Norma Estrada; Charles G. Minard; Richard Hurwitz; Donald H. Mahoney; Amber M. Yates; Mary Vaughan; Alaundra Carmouche; Gladstone Airewele; Susan E. Kirk; Titilope Fasipe; Precious Uwaezuoke; Russell E. Ware

doi:10.1002/ajh.25883

Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease

Alex George, Bogdan Dinu, Norma Estrada, Charles G. Minard, Richard Hurwitz, Donald H. Mahoney, Amber M. Yates, Mary Vaughan, Alaundra Carmouche, Gladstone Airewele, Susan E. Kirk, Titilope Fasipe, Precious Uwaezuoke, Russell E. Ware

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	E242-E244
Journal	American Journal of Hematology
Volume	95
Issue number	9
DOIs	https://doi.org/10.1002/ajh.25883
State	Published - Sep 1 2020

Keywords

Adolescent
Anemia, Sickle Cell/drug therapy
Child
Female
Humans
Hydroxyurea/administration & dosage
Male
Maximum Tolerated Dose

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.25883

Cite this

George, A., Dinu, B., Estrada, N., Minard, C. G., Hurwitz, R., Mahoney, D. H., Yates, A. M., Vaughan, M., Carmouche, A., Airewele, G., Kirk, S. E., Fasipe, T., Uwaezuoke, P., & Ware, R. E. (2020). Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease. American Journal of Hematology, 95(9), E242-E244. https://doi.org/10.1002/ajh.25883

Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease. / George, Alex; Dinu, Bogdan; Estrada, Norma et al.
In: American Journal of Hematology, Vol. 95, No. 9, 01.09.2020, p. E242-E244.

Research output: Contribution to journal › Letter › peer-review

George, A, Dinu, B, Estrada, N, Minard, CG, Hurwitz, R, Mahoney, DH, Yates, AM, Vaughan, M, Carmouche, A, Airewele, G, Kirk, SE, Fasipe, T, Uwaezuoke, P & Ware, RE 2020, 'Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease', American Journal of Hematology, vol. 95, no. 9, pp. E242-E244. https://doi.org/10.1002/ajh.25883

@article{636a448b51a547c3acd12b750dfa3d93,

title = "Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease",

keywords = "Adolescent, Anemia, Sickle Cell/drug therapy, Child, Female, Humans, Hydroxyurea/administration & dosage, Male, Maximum Tolerated Dose",

author = "Alex George and Bogdan Dinu and Norma Estrada and Minard, {Charles G.} and Richard Hurwitz and Mahoney, {Donald H.} and Yates, {Amber M.} and Mary Vaughan and Alaundra Carmouche and Gladstone Airewele and Kirk, {Susan E.} and Titilope Fasipe and Precious Uwaezuoke and Ware, {Russell E.}",

note = "Funding Information: We thank the clinicians, nursing staff, and support personnel of the Texas Childrenʼs Hospital Sickle Cell Center and the staff of the Texas Childrenʼs Clinical Research Office, without whose support we would not have been able to conduct this study. We also acknowledge with deep gratitude the patients and families who participated in this study. This project was supported by a Baylor College of Medicine Department of Pediatrics Pilot Award to Alex George. Funding Information: We thank the clinicians, nursing staff, and support personnel of the Texas Childrenʼs Hospital Sickle Cell Center and the staff of the Texas Childrenʼs Clinical Research Office, without whose support we would not have been able to conduct this study. We also acknowledge with deep gratitude the patients and families who participated in this study. This project was supported by a Baylor College of Medicine Department of Pediatrics Pilot Award to Alex George.",

year = "2020",

month = sep,

day = "1",

doi = "10.1002/ajh.25883",

language = "English (US)",

volume = "95",

pages = "E242--E244",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley",

number = "9",

}

TY - JOUR

T1 - Novel dose escalation to predict treatment with hydroxyurea (NDEPTH)

T2 - A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease

AU - George, Alex

AU - Dinu, Bogdan

AU - Estrada, Norma

AU - Minard, Charles G.

AU - Hurwitz, Richard

AU - Mahoney, Donald H.

AU - Yates, Amber M.

AU - Vaughan, Mary

AU - Carmouche, Alaundra

AU - Airewele, Gladstone

AU - Kirk, Susan E.

AU - Fasipe, Titilope

AU - Uwaezuoke, Precious

AU - Ware, Russell E.

N1 - Funding Information: We thank the clinicians, nursing staff, and support personnel of the Texas Childrenʼs Hospital Sickle Cell Center and the staff of the Texas Childrenʼs Clinical Research Office, without whose support we would not have been able to conduct this study. We also acknowledge with deep gratitude the patients and families who participated in this study. This project was supported by a Baylor College of Medicine Department of Pediatrics Pilot Award to Alex George. Funding Information: We thank the clinicians, nursing staff, and support personnel of the Texas Childrenʼs Hospital Sickle Cell Center and the staff of the Texas Childrenʼs Clinical Research Office, without whose support we would not have been able to conduct this study. We also acknowledge with deep gratitude the patients and families who participated in this study. This project was supported by a Baylor College of Medicine Department of Pediatrics Pilot Award to Alex George.

PY - 2020/9/1

Y1 - 2020/9/1

KW - Adolescent

KW - Anemia, Sickle Cell/drug therapy

KW - Child

KW - Female

KW - Humans

KW - Hydroxyurea/administration & dosage

KW - Male

KW - Maximum Tolerated Dose

UR - http://www.scopus.com/inward/record.url?scp=85087452503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087452503&partnerID=8YFLogxK

U2 - 10.1002/ajh.25883

DO - 10.1002/ajh.25883

M3 - Letter

C2 - 32472611

AN - SCOPUS:85087452503

SN - 0361-8609

VL - 95

SP - E242-E244

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 9

ER -

Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this